Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free INDP Stock Alerts

Indaptus Therapeutics (INDP) Competitors

Indaptus Therapeutics logo
$2.61 -0.16 (-5.78%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$2.61 0.00 (0.00%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

INDP vs. SDGR, WVE, SVRA, MGTX, and COLL

Should you buy Indaptus Therapeutics stock or one of its competitors? MarketBeat compares Indaptus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Indaptus Therapeutics include Schrodinger (SDGR), WAVE Life Sciences (WVE), Savara (SVRA), MeiraGTx (MGTX), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

How does Indaptus Therapeutics compare to Schrodinger?

Indaptus Therapeutics (NASDAQ:INDP) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 9.9% of Indaptus Therapeutics shares are held by insiders. Comparatively, 10.1% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Schrodinger had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for Schrodinger and 2 mentions for Indaptus Therapeutics. Schrodinger's average media sentiment score of 1.26 beat Indaptus Therapeutics' score of 0.44 indicating that Schrodinger is being referred to more favorably in the news media.

Company Overall Sentiment
Indaptus Therapeutics Neutral
Schrodinger Positive

Indaptus Therapeutics has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A
Schrodinger$254.91M4.34-$103.26M-$1.41N/A

Schrodinger has a consensus price target of $20.25, suggesting a potential upside of 35.27%. Given Schrodinger's stronger consensus rating and higher possible upside, analysts plainly believe Schrodinger is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Schrodinger
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33

Indaptus Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Indaptus TherapeuticsN/A -1,030.07% -299.69%
Schrodinger -40.61%-30.85%-15.32%

Indaptus Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Summary

Schrodinger beats Indaptus Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Indaptus Therapeutics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, WAVE Life Sciences had 6 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 8 mentions for WAVE Life Sciences and 2 mentions for Indaptus Therapeutics. WAVE Life Sciences' average media sentiment score of 0.82 beat Indaptus Therapeutics' score of 0.44 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
WAVE Life Sciences Positive
Indaptus Therapeutics Neutral

WAVE Life Sciences currently has a consensus target price of $26.41, indicating a potential upside of 354.59%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe WAVE Life Sciences is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WAVE Life Sciences
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.94
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Indaptus Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WAVE Life Sciences$42.73M26.16-$204.38M-$1.06N/A
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A

WAVE Life Sciences has a beta of -1.29, suggesting that its stock price is 229% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Indaptus Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
WAVE Life Sciences-255.70% -56.76% -42.80%
Indaptus Therapeutics N/A -1,030.07%-299.69%

Summary

WAVE Life Sciences beats Indaptus Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Savara?

Indaptus Therapeutics (NASDAQ:INDP) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 9.9% of Indaptus Therapeutics shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Savara has a consensus price target of $10.14, indicating a potential upside of 84.08%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Savara
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

Savara's return on equity of -87.19% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Indaptus TherapeuticsN/A -1,030.07% -299.69%
Savara N/A -87.19%-66.42%

Savara is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A
SavaraN/AN/A-$118.84M-$0.56N/A

In the previous week, Savara had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 5 mentions for Savara and 2 mentions for Indaptus Therapeutics. Savara's average media sentiment score of 0.72 beat Indaptus Therapeutics' score of 0.44 indicating that Savara is being referred to more favorably in the news media.

Company Overall Sentiment
Indaptus Therapeutics Neutral
Savara Positive

Indaptus Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Savara has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Summary

Savara beats Indaptus Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Indaptus Therapeutics compare to MeiraGTx?

Indaptus Therapeutics (NASDAQ:INDP) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Indaptus Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Indaptus TherapeuticsN/A -1,030.07% -299.69%
MeiraGTx -151.12%N/A -54.96%

Indaptus Therapeutics has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A
MeiraGTx$79.76M13.67-$114.20M-$1.48N/A

In the previous week, Indaptus Therapeutics and Indaptus Therapeutics both had 2 articles in the media. MeiraGTx's average media sentiment score of 1.61 beat Indaptus Therapeutics' score of 0.44 indicating that MeiraGTx is being referred to more favorably in the news media.

Company Overall Sentiment
Indaptus Therapeutics Neutral
MeiraGTx Very Positive

MeiraGTx has a consensus target price of $26.00, indicating a potential upside of 120.90%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts plainly believe MeiraGTx is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
MeiraGTx
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

Indaptus Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Summary

MeiraGTx beats Indaptus Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Collegium Pharmaceutical?

Indaptus Therapeutics (NASDAQ:INDP) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

7.1% of Indaptus Therapeutics shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 63.35%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Collegium Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
3.17

Indaptus Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 9.41% compared to Indaptus Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Indaptus TherapeuticsN/A -1,030.07% -299.69%
Collegium Pharmaceutical 9.41%95.18%16.39%

In the previous week, Collegium Pharmaceutical had 7 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 9 mentions for Collegium Pharmaceutical and 2 mentions for Indaptus Therapeutics. Collegium Pharmaceutical's average media sentiment score of 0.56 beat Indaptus Therapeutics' score of 0.44 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company Overall Sentiment
Indaptus Therapeutics Neutral
Collegium Pharmaceutical Positive

Collegium Pharmaceutical has higher revenue and earnings than Indaptus Therapeutics. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A
Collegium Pharmaceutical$796.33M1.43$62.87M$2.0417.25

Summary

Collegium Pharmaceutical beats Indaptus Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INDP vs. The Competition

Export
MetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$295.56M$3.08B$6.87B$12.26B
Dividend YieldN/A2.07%2.67%9.79%
P/E Ratio-0.1720.2927.1123.64
Price / SalesN/A485.19517.0989.57
Price / CashN/A27.6250.5459.64
Price / Book1.864.1310.286.07
Net Income-$20.85M$65.94M$3.60B$331.99M
7 Day Performance3.16%-4.16%-1.27%-0.63%
1 Month Performance-19.94%-3.76%-0.37%-2.00%
1 Year Performance-73.69%9.94%18.30%13.62%

Indaptus Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INDP
Indaptus Therapeutics
0.3956 of 5 stars		$2.61
-5.8%		N/A-73.6%$295.56MN/AN/A6
SDGR
Schrodinger
2.3329 of 5 stars		$16.27
+0.9%		$20.25
+24.5%		-33.4%$1.19B$254.91MN/A790
WVE
WAVE Life Sciences
3.465 of 5 stars		$5.91
-3.6%		$26.41
+346.9%		-30.8%$1.18B$42.73MN/A240
SVRA
Savara
1.8268 of 5 stars		$5.81
+2.1%		$10.14
+74.6%		+116.1%$1.17BN/AN/A20
MGTX
MeiraGTx
3.9958 of 5 stars		$12.56
+1.0%		$26.00
+107.0%		+41.6%$1.15B$81.39MN/A300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:INDP) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel